Contineum maintains a clean capital structure with a low debt-to-equity ratio of 0.03, though the equity base has contracted to $250.0 million as of 2026Q1.
| Total Current Assets | 252.96M | 267.92M | 206.39M | 127.71M | 48.39M | 69.78M |
| Cash & Short-Term Investments | 246.33M | 262.9M | 204.76M | 125.19M | 47.24M | 69M |
| Cash Only | 20.16M | 75.6M | 21.94M | 15.53M | 5.57M | 4.63M |
| Short-Term Investments | 226.17M | 187.29M | 182.82M | 109.66M | 41.67M | 64.37M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 6.64M | 5.02M | 1.63M | 2.52M | 0 | 0 |
| Total Non-Current Assets | 8.38M | 8.72M | 6.46M | 2.68M | 2.24M | 739K |
| Property, Plant & Equipment | 8.07M | 8.47M | 6.46M | 1.4M | 2.12M | 642K |
| Fixed Asset Turnover | 0.00x | - | - | 35.79x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 312K | 256K | 3K | 1.28M | 129K | 97K |
| Total Assets | 261.35M | 276.64M | 212.85M | 130.39M | 50.64M | 70.52M |
| Asset Turnover | 0.00x | - | - | 0.38x | - | - |
| Asset Growth % | 32.75% | 29.97% | 63.24% | 157.5% | -28.19% | - |
| Total Current Liabilities | 6.66M | 9.74M | 9.97M | 5.48M | 7.55M | 3.67M |
| Accounts Payable | 1.5M | 1.02M | 1.81M | 635K | 430K | 660K |
| Days Payables Outstanding | 6.12K | - | 2.56K | - | - | - |
| Short-Term Debt | 2.3M | 2.34M | 0 | 0 | 3.95M | 1.25M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.86M | 6.39M | 3.37M | 2.48M | 0 | 79K |
| Current Ratio | 38.00x | 27.50x | 20.69x | 23.29x | 6.41x | 18.99x |
| Quick Ratio | 38.00x | 27.50x | 20.69x | 23.29x | 6.41x | 18.99x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 4.65M | 5.91M | 4.81M | 192.84M | 3.82M | 5.26M |
| Long-Term Debt | 4.65M | 5.91M | 0 | 192.62M | 0 | 3.66M |
| Capital Lease Obligations | 4.28M | 0 | 4.81M | 108K | 791K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 110K | 3.02M | 1.6M |
| Total Liabilities | 11.31M | 15.65M | 14.78M | 198.32M | 11.37M | 8.93M |
| Total Debt | 6.95M | 8.25M | 6.26M | 193.19M | 5.85M | 4.91M |
| Net Debt | -13.2M | -67.35M | -15.68M | 177.67M | 280K | 279K |
| Debt / Equity | 0.03x | 0.03x | 0.03x | - | 0.15x | 0.08x |
| Debt / EBITDA | -0.10x | - | - | - | - | - |
| Net Debt / EBITDA | 0.20x | - | - | - | - | - |
| Interest Coverage | - | - | - | 112.39x | -61.51x | -86.35x |
| Total Equity | 250.04M | 260.99M | 198.07M | -67.94M | 39.27M | 61.59M |
| Equity Growth % | 31.74% | 31.77% | 391.55% | -273% | -36.24% | - |
| Book Value per Share | 6.70 | 9.42 | 7.66 | -2.70 | 1.56 | 2.45 |
| Total Shareholders' Equity | 250.04M | 260.99M | 198.07M | -67.94M | 39.27M | 61.59M |
| Common Stock | 37K | 37K | 26K | 2K | 12K | 12K |
| Retained Earnings | -191.84M | -177.38M | -117.4M | -75.14M | -97.86M | -73.61M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -253K | 260K | 71K | 108K | -76K | -35K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial execution dependency
As reported in financial statements, Contineum's equity base has contracted from a peak of $261.0 million in 2025Q4 to $250.0 million in 2026Q1, reflecting the ongoing depletion of capital as the company funds its high-cost R&D programs without offsetting commercial revenue streams.
The downward trajectory in equity highlights the inherent challenge of a pre-revenue biotech model where clinical progress is directly funded by shareholder capital. Investors should monitor whether the current rate of equity consumption necessitates a dilutive financing event before the next major clinical milestone is reached.
Based on Contineum's reported figures, the cash position plummeted from $75.6 million in 2025Q4 to $20.2 million in 2026Q1, indicating a rapid acceleration in liquidity consumption that significantly narrows the company's operational buffer against unforeseen clinical or regulatory delays.
While the current ratio remains high at 38.00, this metric is somewhat deceptive in a pre-revenue context where current assets are almost entirely composed of cash rather than working capital. The rapid decline in cash reserves suggests that the company's runway is shortening, potentially forcing management to prioritize specific pipeline assets over others.
According to recent SEC filings, Contineum's retained earnings have deepened to a deficit of $191.8 million as of 2026Q1, underscoring the persistent nature of the company's losses and the reliance on external equity financing to maintain its operational existence.
The consistent growth of the accumulated deficit is a standard feature of clinical-stage biotechnology, yet it serves as a reminder that the company's equity value is entirely speculative. Future equity quality will likely remain tied to the company's ability to secure non-dilutive milestone payments from its partnership with Johnson & Johnson.
As indicated by the balance sheet, the company's asset base is heavily concentrated in cash with minimal tangible infrastructure, as evidenced by the $8.1 million in net PPE, which suggests that the firm's true value is entirely intangible and tied to intellectual property.
The lack of significant tangible assets means that in a downside scenario, there is virtually no recovery value for shareholders beyond the remaining cash balance. This asset-light structure is typical for the sector but emphasizes that the balance sheet provides no protection against the binary risk of clinical trial failure.
Quick answers to the most common questions about buying CTNM stock.
As of 2025, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) had total assets of $276.6M including $267.9M in current assets.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) carries total debt of $8.3M, offset by $262.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has total shareholders' equity (book value) of $261.0M ($9.42 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported a current ratio of 27.50x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.